The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl B

Carl Borrebaeck


Carl B

Protein Biomarker Signatures in Precision Diagnostics of Cancer


  • Henrik Winther
  • Carl Borrebaeck

Summary, in English

Early diagnosing and patient individualized biomarker profiling are two key elements for curative interventions within cancer. Detecting cancer, when the tumor is still localized, allows for a more efficient treatment-either through surgery alone or with systemic therapies, treating a naïve and less heterogeneous tumor cell population. Developing tumors consist of complex and stage-dependent genetic heterogenous cell-populations. Each cell clone can have different mutation profiles and various protein pathways activated, which often hinders single targeted therapies to embrace all the heterogenous clonalities and therefore leads to drug inefficiency, resistance, and disease relapse. Proteomics and genomics technologies have been used intensively over the last two decades in the revealing of ever more clinical relevant proteins and genetic mutations and alterations. Protein-based profiling assays used for diagnostic, prognostic, predictive, and monitoring purposes are obligated to follow the country-by-country regulatory standards required by authorities with regard to medical devices.


  • LUCC: Lund University Cancer Centre
  • Create Health
  • Department of Immunotechnology

Publishing year







Advances in Medical Imaging, Detection, and Diagnosis

Document type

Book chapter


Jenny Stanford Publishing


  • Cancer and Oncology


  • area under the curve (AUC)
  • assay workflow
  • bioinformatics
  • biomarker
  • biopsies
  • cancer
  • China Food and Drug Administration (CFDA)
  • circulating tumor DNA (ctDNA)
  • clinical accuracy
  • cross-validation
  • diagnostic
  • enzyme-linked immunosorbent assay (ELISA)
  • European Medicines Agency (EMA)
  • genomics
  • hands-on-time (HOT)
  • high-density antibody microarrays
  • immunohistochemistry
  • in vitro diagnostic (IVD)
  • limit of detection
  • limit of quantification
  • mass spectrometry (MS)
  • medical device
  • microarray
  • multiple reaction monitoring (MRM)
  • multiplexing
  • next-generation sequencing (NGS)
  • premarket approval
  • profiling
  • protein
  • proteomics
  • reaction monitoring
  • receiver operating characteristic
  • regulatory considerations
  • responsiveness
  • selected reaction monitoring (SRM)
  • serum
  • specificity
  • turnaround time
  • US Food and Drug Administration (FDA)




  • ISBN: 9789814877466
  • ISBN: 9781000602043